Skip to Main Content

Paper Details

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Clin Gastroenterol Hepatol
40
2019
Author NameAffiliation
Brigid S BolandUniversity of California - San Diego
Brigid S BolandUniversity of California - San Diego
Siddharth SinghUniversity of California - San Diego
Robert HirtenIcahn School of Medicine at Mount Sinai
Eugenia ShmidtUniversity of Minnesota
David HudesmanNew York University
Dana J LukinMontefiore Medical Center
Arun SwaminathLenox Hill Hospital
Corey A SiegelDartmouth-Hitchcock Medical Center
William J SandbornUniversity of California - San Diego
Sunanda V KaneMayo Clinic
Edward V LoftusMayo Clinic
Bruce E SandsIcahn School of Medicine at Mount Sinai
Jean-Frederic ColombelIcahn School of Medicine at Mount Sinai
Parambir S DulaiUniversity of California - San Diego
  • 1 - 15

Datasets

Release 1.2